Dapagli glyflozin Duo Sustained Release Tablet 10/500 mg
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
PharmGen Science Co., Ltd.
MFDS item code 202301898 · Approved 2023.06.21
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication helps improve blood glucose control in adults with Type 2 diabetes when used in combination with dapagliflozin and metformin. It is administered as an adjunct therapy alongside dietary and exercise regimens for more effective blood glucose management. It is especially suitable for patients whose blood glucose is not adequately controlled, and special attention should be given to the effects of dapagliflozin on cardiovascular events for patients with cardiovascular diseases or risk factors based on expert guidelines. This drug is used to effectively control the patient's blood glucose.
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior experience of antidiabetic drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior experience of antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be adjusted gradually to reduce gastrointestinal adverse effects of metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the patient's existing doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering drugs. Since any change may lead to changes in glycemic control, any change in treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2, who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Metformin is excreted through the kidneys, and renal function is more likely to be reduced in older adults; therefore, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).
This medication can rarely cause a serious metabolic complication known as lactic acidosis, so it should not be used in patients with impaired kidney function or those with severe infections or dehydration. Additionally, caution is necessary when taken with insulin or sulfonylurea medications due to the risk of hypoglycemia. It should not be administered to patients with moderate or severe impairment of kidney function or those with acute heart disease or liver dysfunction. Before surgery or radiologic contrast examinations, this medication should be discontinued for a period and re-evaluated based on renal function before re-administration. Women who are pregnant or breastfeeding should not take this medication, and it should also not be administered to patients with lactose intolerance. Elderly patients or those with decreased kidney function should be carefully treated with this medication due to the increased risk of decreased fluid volume and hypotension, and renal function should be monitored regularly. During the use of this medication, infections such as genital, urinary tract infections, and ketoacidosis may occur, so it is important to consult a doctor immediately if symptoms arise. Vitamin B12 deficiency may occur; therefore, it is advisable to monitor serum vitamin B12 levels during prolonged use. Alcohol consumption may increase the risk of lactic acidosis, so excessive drinking should be avoided while taking this medication. This medication can cause hypoglycemia, so immediate appropriate action should be taken if signs of hypoglycemia appear, especially when used in combination with insulin or sulfonylurea, which may require dosage adjustments. Dehydration, hypotension, and changes in renal function as measured by blood tests may occur; therefore, regular monitoring is needed. This medication has not been established for safety and efficacy in children, so it should not be used in that population. In case of overdose, appropriate treatment should be undertaken based on symptoms, and for metformin, dialysis may be beneficial. This drug should be stored out of reach of children, and it should be kept in its original container to prevent degradation in quality and misuse.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly sealed container to prevent exposure to air or moisture. It is important to maintain storage temperatures between 1 and 30 degrees Celsius to preserve its effectiveness.
Pink, bilaterally convex, oval-shaped sustained-release film-coated tablet
30 tablets/box [6 tablets/PTP*5], 30 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
PharmGen Science Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Daewoo Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Il-Yang Pharmaceutical Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Albogen Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.